登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《BioRxiv，3月17日，The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-18

  • The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2

    Erik Procko

    doi: https://doi.org/10.1101/2020.03.16.994236

    Abstract

    The rapid and escalating spread of SARS coronavirus 2 (SARS-CoV-2) poses an immediate public health emergency, and no approved therapeutics or vaccines are currently available. The viral spike protein S binds ACE2 on host cells to initiate molecular events that release the viral genome intracellularly. Soluble ACE2 inhibits entry of both SARS and SARS-2 coronaviruses by acting as a decoy for S binding sites, and is a candidate for therapeutic and prophylactic development. Using deep mutagenesis, variants of ACE2 are identified with increased binding to the receptor binding domain of S at a cell surface.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.biorxiv.org/content/10.1101/2020.03.16.994236v1
24浏览量
原文链接
相关报告

  • 《BioRxiv，3月31日，Computational Design of Peptides to Block Binding of the SARS-CoV-2 Spike Protein to Human ACE2》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-01
    • Computational Design of Peptides to Block Binding of the SARS-CoV-2 Spike Protein to Human ACE2 Xiaoqiang Huang, Robin Pearce, Yang Zhang doi: https://doi.org/10.1101/2020.03.28.013607 Abstract The outbreak of COVID-19 has now become a global pandemic and it continues to spread rapidly worldwide, severely threatening lives and economic stability. Making the problem worse, there is no specific antiviral drug that can be used to treat COVID-19 to date. SARS-CoV-2 initiates its entry into human cells by binding to angiotensin-converting enzyme 2 (hACE2) via the receptor binding domain (RBD) of its spike protein. Therefore, molecules that can block SARS-CoV-2 from binding to hACE2 may potentially prevent the virus from entering human cells and serve as an effective antiviral drug. Based on this idea, we designed a series of peptides that can strongly bind to SARS-CoV-2 RBD in computational experiments. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    23浏览量
    原文链接

  • 《bioRxiv，5月17日，Binding of the SARS-CoV-2 Spike Protein to Glycans》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-18
    • Binding of the SARS-CoV-2 Spike Protein to Glycans Wei Hao, Bo Ma, Ziheng Li, Xiaoyu Wang, Xiaopan Gao, Yaohao Li, Bo Qin, Shiying Shang, Sheng Cui, Zhongping Tan doi: https://doi.org/10.1101/2020.05.17.100537 Abstract The 2019 novel coronavirus (SARS-CoV-2) is the seventh human coronavirus. The pandemic of this virus has caused a high number of deaths in the world. In order to more efficiently combat this pandemic, it is necessary to develop a better understanding of how the virus infects host cells. Infection normally starts with the initial attachment of the virus to cell-surface glycans like heparan sulfate (HS) proteoglycans and sialic acid-containing oligosaccharides. In this study, we used glycan microarray technology to study the binding of the SARS-CoV-2 spike protein (S protein) to HS and sialic acid. Our results indicated that the S protein can bind to HS in a sulfation-dependent manner and the length of HS appears not to be a critical factor for the binding. No binding with sialic acid residues was detected. In addition, we applied sequence alignment and molecular docking to analyze and explain the observed binding results. Our results suggested that HS may stabilize the open conformation of the S protein to promote the subsequent binding of the S protein to the virus entry receptor ACE2. Overall, this work supports the potential importance of HS in SARS-CoV-2 infection and in the development of antiviral agents.
    23浏览量
    原文链接